Serevent “Manipulated” Data Shows Need For Transparency – Public Citizen
Executive Summary
GlaxoSmithKline's handling of Serevent risk data from the SMART study demonstrates the need for greater transparency in the FDA review process, Public Citizen's Health Research Group suggests in a letter to The Lancet
You may also be interested in...
Serevent, Foradil Use With Steroids Should Be Strongly Urged In Labeling
Labeling for GSK's Serevent and Novartis/Schering's Foradil should include a stronger recommendation that the long-acting beta agonist bronchodilators be used concomitantly with inhaled corticosteroids, FDA's Pulmonary-Allergy Drugs Advisory Committee said
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials